Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
PT Medela Potentia Tbk
MDLA
Sector: Healthcare
Industry: Pharmaceuticals
Sub Sector: Pharmaceuticals & Health Care Research
Sub Industry: Pharmaceuticals
Live quote
tidak tersedia
tidak tersedia
Highlight Keuangan (2026 Q2) (In Rp)
EPS
32
ROE
14,37%
ROA
6,69%
Book Value
219
Net Income
220,95 M
Total Sales
8,17 T
Total Assets
6,61 T
DER
1.12x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
3,95%
23,98%
20,98%
20,98%
8,99%
4,03%
1,16%
Tentang Perusahaan
PT Medela Potentia Tbk. (Company) was established based on Deed of Establishment No. 04 dated August 5, 2011, of Public Notary Evy Ferdiana, S.H, Notary of Bekasi Regency, domiciled in Lemah Abang. The Company started its operation activities in 2013.
Produk & Lini Bisnis
The Company is the parent entity of the Group that is engaged in the distribution and marketing of pharmaceutical products, health products, and medical devices. It also manufactures medical devices and implements web portals and/or digital platforms for commercial purposes through its subsidiaries
Dewan Direksi
KP
Krestijanto Pandji
President Director
EO
Edbert Orotodan
Director
WW
Wimala Widjaja
Director
Dewan Komisaris
SC
Stanley CH. Budihardja
President Commissioner
LS
Lukas Setia Atmaja Msc.
Independent Commissioner
Anak Usaha & Afiliasi
| Nama | Domisili | % |
|---|---|---|
| PT. Djembatan Dua Trading of Pharmaceutical Products, medical devices, consumer and healthcare products, services |
Jakarta | 99.90% |
| PT. Anugrah Argon Medica Trading pharmaceutical products |
Tangerang | 99.99% |
| Dynamic Argon Co.Ltd. Trading pharmaceutical products |
Cambodia | 75.00% |
| PT. Deca Metric Medica Medical devices product Processing industry |
Bekasi | 99.90% |
| PT. Karsa Inti Tuju Askara Web portal and digital platforms
|
Tangerang | 51.00% |
Trend Keuangan (5 periode terakhir)
— hover bar untuk detail
Total Sales
Net Income (+)
Net Income (-)
2025 Q2
EPS 28
ROE 13,30%
2025 Q3
EPS 28
ROE 13,19%
2025 Q4
EPS 28
ROE 12,92%
2026 Q1
EPS 33
ROE 14,83%
2026 Q2
EPS 32
ROE 14,37%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
| Periode | Total Sales | Net Income | Total Assets | Total Equity | EPS | ROE | DER |
|---|---|---|---|---|---|---|---|
| 2026 Q2 | 8,17 T | 220,95 M | 6,61 T | 3,08 T | 32 | 14,37% | 1.12x |
| 2026 Q1 | 4,03 T | 116,66 M | 6,89 T | 3,15 T | 33 | 14,83% | 1.16x |
| 2025 Q4 | 14,89 T | 392,27 M | 6,58 T | 3,04 T | 28 | 12,92% | 1.14x |
| 2025 Q3 | 11,09 T | 289,63 M | 6,50 T | 2,93 T | 28 | 13,19% | 1.19x |
| 2025 Q2 | 7,42 T | 197,95 M | 6,26 T | 2,98 T | 28 | 13,30% | 1.08x |
History Harga Penutupan & Book Value
| Tahun | Qrt | Close Price (Rp) | Book Value (Rp) | ROA |
|---|---|---|---|---|
| 2026 | 2 | 202 | 219 | 6,69% |
| 2026 | 1 | 210 | 225 | 6,77% |
| 2025 | 4 | 264 | 217 | 5,96% |
| 2025 | 3 | 226 | 209 | 5,94% |
| 2025 | 2 | 197 | 213 | 6,32% |
Data diperbarui pada: 2026-05-12 11:14:16